Breast cancer biomarker (ER, PR, HER2) changes in the phenotype after neoadjuvant treatment

Breast cancer biomarker (ER, PR, HER2) changes in the phenotype after neoadjuvant treatment

Objective: to study the breast cancer phenotype (ER/PR, FOXA1, HER2, Ki67) and the dynamics of changes in these markers in the tumour before and after neoadjuvant chemotherapy (NAT), compare them with metastases in the regional lymph nodes (LN). Materials and methods. The subject of the study was a...

Full description

Bibliographic Details
Main Authors: V. O. Bashlyk, A. G. Kudaibergenova, A. S. Artemyeva, A. L. Muravtseva, V. S. Chirsky, T. Yu. Semiglazova, V. V. Klimenko, V. F. Semiglazov
Format: Article
Language:Russian
Published: Remedium Group LLC 2018-07-01
Series:Медицинский совет
Subjects:
breast cancer
neoadjuvant chemotherapy
tumor immunophenotype
Online Access:https://www.med-sovet.pro/jour/article/view/2547

Internet

https://www.med-sovet.pro/jour/article/view/2547

Similar Items